Diflorasone is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. It is available as cream and ointment for topical use. MedsAcross supplies Diflorasone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
INDICATION AND USAGE Diflorasone diacetate cream USP, 0.05% is a high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Source: US FDA prescribing information
Diflorasone diacetate cream USP, 0.05% should be applied to the affected area twice daily.
Source: US FDA prescribing information
Diflorasone diacetate cream USP is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Source: US FDA prescribing information
General Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment. Patients receiving a large dose of a higher potency topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression. This may be done by using the ACTH-stimulation, A.M. plasma cortisol, and urinary free-cortisol tests. This product has a greater ability to produce adrenal suppression than does diflorasone diacetate ointment USP, 0.05%.
Source: US FDA prescribing information
The following local adverse reactions have been reported infrequently with other topical corticosteroids, and they may occur more frequently with the use of occlusive dressings, especially with higher potency corticosteroids. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infections, skin atrophy, striae, and miliaria.
Source: US FDA prescribing information
Store at 20 ° to 25 ° C (68 ° to 77 ° F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Diflorasone, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Diflorasone 0.05% ointmentTopicalGeneric name | — | US FDA | Available on request |
| Diflorasone 0.05% creamTopicalGeneric name | — | US FDA | Available on request |
| psorcon 0.5% creamTopical | Sun Pharmaceutical IndustriesIndia | US FDA | Available on request |
1 brand names across 1 markets.
United States
Indian manufacturers are highlighted.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 14 September 1977 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Diflorasone in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 3 presentations of Diflorasone and sources them for licensed hospitals, importers and physicians against valid import documents. Indian manufacturers include Sun Pharmaceutical Industries.
The catalogue lists 1 brand names for Diflorasone, including psorcon.
Yes. The US FDA first approved Diflorasone on 14 September 1977, according to Drugs@FDA.
No listed presentation of Diflorasone is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Diflorasone is classified under ATC code D07AC10 (Diflorasone).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.